Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
NCT ID NCT07422337
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus, hepatitis B, and measles. If protection is low, they will see if re-vaccination can restore it. The goal is to create a clear vaccination plan for these patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Potential participants will be identified through referrals and from medical records. Prospective participants are those who have been captured prior to starting chemotherapy, and retrospective participants are those who have been captured after starting chemotherapy or have finished chemotherapy within the previous 12 months.
- Ages
-
1 year to 23 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of B-lineage acute lymphoblastic leukemia/lymphoma * ≥1 year old and up to 21 years old at diagnosis * Informed consent provided, and if applicable, child assent provided * Must have received all vaccinations routinely administered during first year of life Exclusion Criteria: * Relapsed/refractory disease at any time * Received or will require a bone marrow transplant and/or cellular therapy * Pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B cell ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Arkansas Children's
RECRUITINGLittle Rock, Arkansas, 72202, United States
-
Arkansas Children's Northwest
RECRUITINGSpringdale, Arkansas, 72762, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental therapy SNC116 put to the test against Hard-to-Treat leukemia
- Can a Pre-Transplant drug keep leukemia from returning?
- Fighting fat to fight leukemia: could a diet and exercise plan boost chemo?
- Can a new combo drug tame childhood leukemia that Won't quit?
- Can engineered immune cells outsmart resistant blood cancers?
- Can donor immune cells be engineered to fight blood cancer?